U.S. Markets closed

The Zacks Analyst Blog Highlights: FirstEnergy, Synchrony Financial, ExxonMobil, Morgan Stanley and Bristol-Myers

Zacks Equity Research

For Immediate Release

Chicago, IL – May 2, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ExxonMobil XOM, Morgan Stanley MS, Bristol-Myers BMY, FirstEnergy FE and Synchrony Financial SYF.

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for ExxonMobil, Morgan Stanley and Bristol Myers

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil, Morgan Stanley and Bristol-Myers. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

ExxonMobil’s shares have outperformed the Zacks Integrated International Oil industry (+7.2% vs. +1.5%) over the past three months. The Zacks analyst thinks ExxonMobil has a leading position in the energy industry owing to its size and diverse asset base, both in terms of business mix and geographical footprint.

With a stable cash position, the company’s balance sheet is one of the best in the industry. This has allowed ExxonMobil to reward stockholders with a 6.2% average annual dividend hike over the past 37 years. The company owns some of the most prolific upstream assets globally. Notably, with three fresh offshore oil discoveries in Guyana, ExxonMobil recently completed 13 key discoveries in the Stabroek Block.

However, the integrated energy firm recently reported weak first-quarter 2019 results due to significant lower contributions from downstream and chemical businesses. Significant scheduled maintenance activities and the contraction in fuel margin hurt ExxonMobil’s downstream business, whereas the chemical business was hurt by soft margin.

(You can read the full research report on ExxonMobil here >>>).

Shares of Morgan Stanley have gained +5.5% over the past six months, outperforming the Zacks Investment Banking industry, which has declined -3.6% over the same period. The company possesses an impressive earnings surprise history, having beaten expectations in three of the trailing four quarters. Its first-quarter 2019 results were driven by higher net interest income and decline in costs.

The Zacks analyst thinks the deal to acquire Solium Capital is in sync with the company’s efforts to strengthen its wealth management business. Focus on corporate lending unit, steady loan growth, higher interest rates and normalized levels of trading activities will likely aid revenues. Also, its steady capital deployments indicate a strong liquidity position.

However, slowdown in debt originations will hinder underwriting fee income growth and hurt the company’s investment banking performance. Further, elevated operating expenses remain a major near-term concern.

(You can read the full research report on Morgan Stanley here >>>).

Bristol-Myers’ shares have underperformed the Zacks Large Cap Pharmaceuticals industry in the past six months, losing -8.9% vs. +0.6%. Bristol-Myers beat on both earnings and sales in the first quarter, primarily on robust sales of Opdivo and Eliquis. The Zacks analyst thinks the company’s efforts to develop pipeline products like Opdivo are encouraging.

In January, Bristol-Myers announced that it will acquire Celgene for an equity value of approximately $74 billion to bolster its portfolio. While the deal was previously being opposed by a few shareholders, the merger has now been given a green signal.

However, the company’s voluntary withdrawal of the sBLA seeking approval of Opdivo+Yervoy for the treatment of first-line NSCLC with tumor mutational burden greater or equal to 10 mutations/megabase following discussions with the FDA was disappointing, given the market potential. Competition has stiffened for Opdivo from Merck’s Keytruda and Roche’s Tecentriq.

(You can read the full research report on Bristol-Myers here >>>).

Other noteworthy reports we are featuring today include FirstEnergy and Synchrony Financial.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com                                                   

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
FirstEnergy Corporation (FE) : Free Stock Analysis Report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Morgan Stanley (MS) : Free Stock Analysis Report
 
Synchrony Financial (SYF) : Free Stock Analysis Report
 
Exxon Mobil Corporation (XOM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research